Pulmonx Corp (NAS:LUNG)
$ 8.01 -0.06 (-0.74%) Market Cap: 310.91 Mil Enterprise Value: 237.69 Mil PE Ratio: 0 PB Ratio: 2.81 GF Score: 60/100

Pulmonx Corp at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2022 / 08:40PM GMT
Release Date Price: $20 (-3.47%)
Cecilia E. Furlong
Morgan Stanley, Research Division - Equity Analyst

Good afternoon, and welcome to the second day -- nearly the end of the second day of the Morgan Stanley Healthcare Conference. I am Cecilia Furlong, medical device analyst here at Morgan Stanley. It is my pleasure to have Pulmonx with us; CEO, Glen French; CFO, Derrick Sung. Thank you both for being here today.

Glendon E. French
Pulmonx Corporation - CEO, President & Director

Thank you.

Questions & Answers

Cecilia E. Furlong
Morgan Stanley, Research Division - Equity Analyst

And I think we've started a lot of these conversations with macro. I'd love to start with CONVERT given what we've heard recently from a data standpoint. But as you think about just for the field? What's the greatest potential benefit as you contemplate further adoption?

Glendon E. French;Cecilia E. Furlong
Pulmonx Corporation - CEO, President & Director

Specific to CONVERT or...

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot